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Abstract
Pregnancy in women with Sickle Cell Disease (SCD) has been linked with an increased
incidence of adverse foetal outcomes when compared to women without haemoglobinopa-
thies (HbAA). There’s a paucity of data into foetal outcomes for infants born to women with
SCD. Customised growth charts have been demonstrated to be better than population-
based growth charts at identifying unhealthy small babies. We analysed the mean birth
weight and customised birth weight centiles of infants born to mothers with SCD versus
mothers with HbAA genotype, to quantify the risk of having a smaller baby. Birth weight and
birth weight centiles were analysed for 88 women with SCD (50 HbSS; 38 HbSC) and 176
controls (HbAA). Statistically significant differences were seen in the mean birth weight
(P value = 0.004) and the mean birth weight centiles (P value = 0.016). We conclude that
SCD is a risk factor for having a smaller baby.
Introduction
The clinical care for Sickle Cell Disease (SCD) has vastly improved the quality and longevity of
those affected. Pregnancies in this cohort, however, still carry a greater risk of unfavourable
pregnancy outcomes [1]. The major types of SCD are: Sickle Cell Anaemia (HbSS), Sickle cell-
Haemoglobin C disease (HbSC) and Sickle Cell β-Thalassaemia (HbSβthal) [2]. There is a pau-
city of data into foetal outcomes for infants born to women with SCD [3].
A meta-analysis of 26,823 SCD pregnancies (HbSS n = 1,523, HbSC n = 331, unspecified
SCD genotype n = 24,969) showed a greater relative risk (RR) of small for gestational age
(SGA) when analysed against women with normal haemoglobin (HbAA) (HbSS RR = 3.72,
HbSC RR = 1.98) [1]. A Jamaican retrospective cohort of study of n = 118 HbSC and n = 110
HbAA pregnancies showed an increased rate of low birth weight (LBW) (HbSC 22.9%, HbAA
5.5%, p<0.0001) [4]. A UK nationwide cohort study of 109 SCD pregnancies (HbSS n = 55,
HbSC n = 44, other SCD n = 11, unknown SCD genotype n = 3) based on data extracted from
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the United KingdomObstretric Surveillance Study (UKOSS) showed an overall higher preva-
lence of LBW in babies born to mothers with SCD (23.3%, p<0.001) compared to HbAA
mothers, as well as an increased rate of LBW in babies born to HbSS versus HbSCmothers
(HbSS 35.4%, HbSC 14%, p = 0.025) [5].
The existing data are based on population-based estimates, which do not adjust for the effect
of maternal ethnicity and parity on birth weight [6,7]. The purpose of this study is to determine
whether or not infants born to women with SCD are more prone to LWB, SGA and intrauter-
ine growth restriction (IUGR) than infants born to women without SCD [2]. As far as we are
aware, this study is novel in its use of customised birth weight growth charts to accurately
investigate the relationship betweenmaternal SCD and birth weight [8].
Materials and Methods
A retrospective cohort study was carried out on the birth weights of the newborns of mothers
with SCD delivering at St Thomas’ Hospital between 2008–2013. St Thomas’ Hospital is a
teaching hospital in London, UK which provides specialist tertiary care to a metropolitan
patient population. Every pregnant woman receiving treatment at our department is offered
and can opt to undergo haemoglobinopathy screening [8,9].
We looked at the influence of maternal SCD on birth weight, with reference to the following
maternal physiological factors: bodymass index (BMI), ethnicity and the number of previous
births; and infant outcomes: sex and gestational age at birth. Data were extracted from an elec-
tronic clinical database (Terranova Healthware). The midwife attending the delivery had
recorded data on the database. These data were used to generate a customised birth weight pre-
diction, which was compared to the infant’s actual weight at birth using the UK Gardosi Bulk
Centile Calculator Version 6.6 [8]. This version of the software uses the gestation related opti-
mal weight standard (GROW) based specifically on the UK population [10].
Data were only included from singleton pregnancies, because pregnancies involving more
than one foetus are susceptible to considerable foetal growth and weight differences [8,11]. In
addition, only women with diagnosed SCD were included in the study population—thosewith
sickle cell trait (SCT) were excluded. Pregnancies in women with SCT are not predisposed to
impaired birth weight, as evidencedby a recent UK cohort study [8].
Customised growth chart calculators control for healthy growth variations due to: ethnicity,
parity, maternal habitus, gender and gestational age at delivery. Population-based growth
charts thus do not accurately distinguish between permissible (non-pathologically) and patho-
logically small neonates, whereas customised growth charts do [8]. Customised growth charts
have been shown to be better at identifying small babies than population-based growth charts
[6]. Data were analysed using the UK Gardosi customised growth chart calculator [8]. The UK
Gardosi Bulk Centile Calculator predicts the Terminal OptimalWeight (the foetus’ growth
potential) by incorporating the following physiological factors: maternal ethnicity, parity,
height and weight at the time of booking, gestation at delivery (determined by ultrasound anal-
ysis) and the foetus’ gender and birth weight. These variables were extracted fromHealthware
and entered into the UK Gardosi Bulk Centile Calculator Version 6.6 to generate birth weight
centiles [8,12].
Women were matched by age at delivery, parity and ethnicity to control for birth weight
variations pertaining to ethnicity and parity. Although this is a cohort study, the matching
allowed the control population to be as representative of the study population in as many
aspects as could be controlled for, so as to enable any differences in the results to be representa-
tive of the difference in haemoglobin status rather than normal physiology [13]. The upper and
lower limits of the birth weight centiles on the customised growth chart were used to more
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accurately identify atypical growth. LBW is defined as weighing 2.5kg or less [8]. SGA describes
neonates with a birth weight ranked at or below the 10th centile for gestation [7].
The study population incorporated all eligible women with SCD and the control population
included all eligible women without SCD. The SCD group was stratified according to SCD type
into HbSS and HbSC. Statistical analyses were made comparing SCD group against the control
group, and the stratifiedHbSS and HbSC groups against the controls, using Stata 14. Given the
heterogeneity of SCD, the purpose of the latter was to enable specific analysis of the impact on
haemoglobin status on foetal growth [14].
Statistical differences and 95% confidence intervals were generated using logistic regression
to analyse the birth weight and birth weight centiles in the study and control groups. Differ-
ences in the mean maternal age, BMI, gestational age and birth weight were estimated along
with their 95% confidence intervals. T-value was performed to obtain the p-value for the differ-
ence, and the null hypothesis defined as a difference being equal to 0. For variables expressed
as proportions (parity, sex, birth weight centile, LBW and SGA) we performed logistic regres-
sion to identify any differences in the proportions for the SCD and HbAA group [6,7,14,15].
Results
Birth weight and birth weight centiles were analysed for infants born to 88 women with SCD
(50 with HbSS and 38 with HbSC genotype, respectively) and 176 controls (HbAA) (same eth-
nicity, age, parity and gestation) Table 1. Statistically significant differences were seen in mean
birth weight (P value = 0.004) and mean birth weight centiles (P value = 0.016) Table 1. The
mean age was 29.6 years in both the SCD group (28.5 years in HbSS; 31.0 years in HbSC
groups) and control group (P value = 0.98). The mean BMI in the SCD group was 25.0 kg/m2
(22.5 kg/m2 in HbSS and 28.3 kg/m2 in HbSC groups) and 27.3 kg/m2 in the control group
(P value = 0.003). There were no statistically significant differences in the rates of SGA or LBW
amid the SCD and HbAA groups Table 2.
Table 1. Characteristics of study groups.
SCD (n = 88) HbSS (n = 50) HbSC (n = 38) HbAA (n = 176) Difference (SCD vs. HbAA) P value¶
Maternal Age (years)* 29.6 (5.6) 28.5 (5.7) 31.0 (5.1) 29.6 (5.4) 0.02 (95% CI: -1.4,1.4) 0.98
BMI (kg/m2)* 25.0 (6.2) 22.5 (3.2) 28.3 (7.6) 27.3 (5.5) 2.27 (95% CI: 0.79,3.75) 0.003
Nulliparous (%)^ 53.4% 60.0% 44.7% 52.8% 0.6% 0.931
Ethnicity (%)^
Black British 28.4% 30.0% 26.3% 28.4% 0 1
Black African 63.6% 66.0% 60.5% 63.6% 0 1
Black Other 8.0% 4.0% 13.2% 8.0% 0 1
Gestational age (weeks)* 38.3 (2.5) 38.1 (2.1) 38.5 (2.9) 38.7 (2.7) 0.44 (95% CI: -0.23,1.12) 0.20
Female infant (%)^ 52.3% 62.0% 60.5% 50.6% 1.7% 0.79
Birth weight (g)* 2918 (587) 2858 (505) 2998 (678) 3176 (720) 258.4 (95% CI: 83.9,432.8) 0.004
Birth weight centile (%)* 32.8 (24.3) 33.0 (23.7) 42.2 (32.1) 42.1 (32.1) 9.4 (95% CI: 1.8,17.1) 0.016
LBW (%) 15.9% (14) 18.4% (9) 14.0% (5) 10.8% (19) 5.1% (95% CI: -3.8%, 14.0%) 0.239
SGA (%) 23.9% (21) 18.0% (9) 31.6% (12) 20.5% (36) 3.4% (95% CI: -7.3%, 14.1%) 0.526
*Values are mean (SD)
¶Statistically significant (P value <0.05)
^Logistic regression
SD = standard deviation *Matched variables—hence no statistically significant difference.
doi:10.1371/journal.pone.0165238.t001
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The main differences between the SCD and control group were the mean birth weight and
mean birth weight centile. The overall mean birth weight for the SCD pregnancies was 2918g
compared to a mean birth weight of 3176g for the controls. The mean birth weight of the
neonates born to SCDmothers was significantly lower at 258g below that of the HbAA coun-
terparts (P value = 0.004). In keeping with this, the mean birth weight centile for the SCD
deliveries (32.8th centile) was significantly lower than the controls (42.2nd centile) with a dif-
ference of 9.4 centiles (P value = 0.016) Table 1. The median birth weight was 3025g (inter-
quartile range = 2740-3270g) for the SCD group and 3200g (interquartile range = 2890-
3545g) for the controls.
The preterm birth rate (defined as birth prior to the 37th week of gestation) was 10.2%
(n = 9) for the SCD group (95% CI = 5.3%-18.7%) and 9.1% (n = 16) for the control group
(95% CI = 5.6%-14.4%) [1]. There was no significant difference between the ethnicities of our
study and comparator group; however, this was to be expected given that we matched our con-
trol group according to ethnicity Table 1.
Discussion
Key findings
Statistically significant differences were seen in mean birth weight (P value = 0.004) and mean
birth weight centiles (P value = 0.016). Inadequate foetal development and/or premature labour
can cause LBW [16]. Babies born SGA are more susceptible to disease and death in utero or
after birth. Affected infants may have impaired growth and/or cognitive development, and in
adult life may be susceptible to heart and vascular problems [17]. Pregnancies in women with
SCD are at increased risk of maternal mortality, pre-eclampsia, preterm delivery and stillbirth;
such complications may prevent the developing foetus achieving its growth potential in utero
[1,2].
Interpretation of findings
A neonate may exceed the threshold for SGA and still be growth restricted. IUGR reflects an
infant who has been unsuccessful in attaining his or her personal optimal growth [13]. Our
findings demonstrate that SCD deliveries are more at risk of smaller babies than non-SCD
deliveries. There was no significant difference between the ethnicity, parity or age of the
women in the SCD and control group, which further implicates SCD as the cause of the lower
mean birth weight and mean birth weight centiles in the SCD group [7,18].
Gestational age at delivery is influenced by: maternal age at delivery, socioeconomic status,
pathology, number of previous births, demographics, a history of preterm birth and smoking.
Mothers of Black and Asian ethnicity have been shown to deliver earlier compared to white
counterparts [19]. LBW has been linked with first-timemothers [20]. By matching our SCD
population and controls, we ensured that there were no significant differences in the parity,
gestational age at delivery, age or ethnicity of the women in our study population and matched
Table 2. Adjusted Odds ratios for SCD versus HbAA.
SCD (n = 88) HbAA (n = 176) Adjusted Odds ratio (SCD vs. HbAA) P value¶
LBW (%)^ 15.9% (14) 10.8% (19) 1.56 (95% CI: 0.74, 3.29) 0.239
SGA (%)^ 23.9% (21) 20.5% (36) 1.22 (95% CI: 0.66, 2.25) 0.526
¶Statistically significant (P value <0.05)
^Logistic regression.
doi:10.1371/journal.pone.0165238.t002
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controls Table 1. Variations in these physiological factors are therefore unlikely to account for
the statistically lower birth weight and birth weight centiles seen in our SCD group [19].
Our SCD group had a significantly lower mean BMI than our controls Table 1. Maternal
BMI is an important consideration when assessing foetal growth, in particular birth weight.
Women with a diagnosis of HbSS tend to have a lower body habitus than their HbAA counter-
parts. Our findings are consistent with this observation [15].
Alarmingly, a number of the controls were overweight (BMI between 25 and 29.9) or obese
(BMI30) [21]. The BMI difference has little statistical significance to the results, as the cus-
tomised growth calculator takes maternal body habitus into consideration [13]. The findings
do, however, highlight a separate issue of maternal obesity in this cohort and its implications
on foetal outcomes [21].
Maternal obesity during pregnancy exposes the foetus to increasedmorbidity and mortality
in the short- and long-term, including perinatal death and being large for gestational age
(LGA) (at or above the 90th centile for birth weight for gestation at delivery and sex), and heart
disease in later life, respectively [21,22]. Putting on weight is important during pregnancy for
optimal foetal development. An Australian cohort study also using customised growth charts
to quantify the relationship between increases in weight during pregnancy and birth weight
demonstrated a significant relationship between extreme and insufficient increases in weight
during gestation and higher rates of LGA and SGA, respectively [21]. Lower socioeconomic
status has been correlated with poorer foetal outcomes. It is plausible, but unlikely, that this
explains the statistical differences between the mean birth weights and mean birth weight cen-
tiles [11].
Babies born to black mothers have been shown to be more likely to be of LBW when com-
pared to babies born to white mothers. A UK study quantified a 60% increased risk of LBW
amongst black babies compared to white babies [22]. Customised growth charts adjust for eth-
nicity, which offers the aforementioned benefit of discerning pathologically from non-patho-
logically small babies [22,23].
Strengths and limitations of this study
The uniqueness of this study is that through the use of the customised growth chart we have
more accurately ascertained the relationship between SCD and birth weight. As far as we are
aware, this study is novel in its use of customised birth weight growth charts to accurately
investigate the relationship betweenmaternal SCD and birth weight [8].
Both active and passive smoking during pregnancy have been linked with IUGR. There was
only one smoker in our SCD population, thus it is highly improbable that the significant
growth restriction seen in our results relates to smoking as opposed to SCD [10].
The customised growth chart does not adjust for maternal or gestational pathologies, for
example gestational hypertension which is known to affect birth weight [8,21]. Problems with
the placenta, mother and/or foetus may underpin the reason for higher rates of IUGR in
patients with SCD [7,18].
Clinical relevance and future areas of research
This study is the first to quantify the impact of SCD on birth weight and birth weight centiles
using customised growth charts. The findings presented are therefore novel in that the analyses
take into consideration the healthy differences, including maternal ethnic and anthropometric
diversity, parity, gender and the stage of gestation at birth. Our study demonstrates that
although SCD is a risk factor for smaller babies, adjustment for confounders and using the Gar-
dosi customised growth chart still demonstrates a strong evidence of IUGR in women with
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SCD in pregnancy. This has important clinical implications given the association between
lower birth weight and unfavourable outcomes [6,7,15].
At present, we lack intrauterine interventions to cure IUGR. The identification of IUGR
facilitates strategic timing of birth (e.g. induction) to optimise the baby’s prospects. Our find-
ings emphasise the importance of regular detailed routine non-invasive monitoring for indica-
tors of IUGR in the management of all SCD pregnancies [10].
Our study identifies several areas for future research. Firstly, problems with the placenta
may underpin the IUGR [7,18]. The precise pathophysiology underlying the propensity for
smaller babies in women with SCD remains elusive. The placenta plays a pivotal role in foetal
development, providing a critical gateway betweenmother and child to supply nutrients, oxy-
gen and other such growth enhancing components. Impairments in the placenta may have dev-
astating effects on the health of the unborn child. Placental abnormalities have been proposed
to be the basis for many foetuses failing to achieve their optimal growth. Vaso-occlusive crisis
occurring in the placenta may bring about tissue ischemia and death, thus threatening the via-
bility of the placenta [24]. Prolonged hypoperfusion and poor oxygenation are likely to impair
the growth of the developing foetus [25]. Aberrant vascular remodelling has been shown to be
central to the pathophysiology of preeclampsia [26]. Preeclampsia is fourfold more likely to
occur in HbSS pregnancies [1].
Asymmetrical IUGR affecting the third trimester has been seen in SCD pregnancies [27]. A
study using umbilical arterial doppler assessment to assess intrauterine growth in HbSS preg-
nancies demonstrated a relationship between increased arterial impedance and lower birth
weight. These findings highlight a relationship between uteroplacental insufficiencyand mater-
nal SCD [28]. Uncovering the mechanisms behind the IUGRwould be the cornerstone to
developing preventative measures and interventions to improve placental function [29].
Secondly, the impact of SCD, notably HbSS on preconception BMI and pregnancy weight
gain [21]. Thirdly, the significant risk of small babies in this patient cohort may have significant
lifelong developmental implications on the offspring of women with SCD. Our study therefore
flags up the importance of paediatric childhooddevelopmental follow up of the offspring of
this cohort of patients, especially given the hypothesis that future adult diseasemay be related
to early life development–the Barker and the Developmental Origins of Adult Health and Dis-
ease theories [29].
This study is the first to quantify the impact of SCD on birth weight and birth weight cen-
tiles using customised growth charts. We conclude that SCD is a risk factor for smaller babies
[6].
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